Trials / Completed
CompletedNCT02433457
Relative Bioavailability Study of CC-292
An Open-label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect and Dose Proportionality of CC-292 Spray Dried Dispersion Formulation in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the PK profile of the newly developed CC-292 SDD formulation compared to CC-292 P22 tablet.
Detailed description
This is a single center, open-label, randomized, seven-treatment, seven-period, crossover design. The study will consist of a screening phase, a treatment phase, and a follow-up phone call. Approximately 24 healthy adult subjects (male or female) will be enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-292 | |
| DRUG | Oral Omeprazole (OMP) |
Timeline
- Start date
- 2014-05-26
- Primary completion
- 2014-09-26
- Completion
- 2014-09-26
- First posted
- 2015-05-05
- Last updated
- 2020-08-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02433457. Inclusion in this directory is not an endorsement.